Could a simple inhaled gas replace morphine for heart attack pain?

NCT ID NCT07445737

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 3 trial will compare methoxyflurane (Penthrox®), a painkiller gas patients inhale themselves, against standard morphine injections for chest pain during a heart attack. About 700 adults with a specific type of heart attack (STEMI) will be enrolled in pre-hospital settings. The goal is to see if methoxyflurane is at least as good as morphine at relieving pain within 30 minutes, with fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Methoxyflurane (Penthrox®) inhaled gas
What this could lead to
If it works, this could offer a faster, easier-to-use pain relief option for heart attack patients without needing an IV line.
What could go wrong
This is a non-inferiority trial, so it may only show methoxyflurane is not worse than morphine, not necessarily better. It has not started recruiting yet, and results may not apply to all heart attack patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STEMI - ST ELEVATION MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital Avicenne

    Bobigny, 93000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.